WOMEN IN REPRODUCTIVE SCIENCE

My WOMBan’s life: understanding human endometrial function

Lois A Salamonsen

Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria, Australia

Correspondence should be addressed to L A Salamonsen; Email: lois.salamonsen@hudson.org.au

This paper forms part of a special issue on Women in Reproductive Science. The guest editor for this section was Professor Marilyn Renfree, Ian Potter Chair of Zoology, School of BioSciences, The University of Melbourne, Victoria, Australia

Abstract

The focus of my life in science has been to improve reproductive health for women, with an emphasis on the endometrium, the most dynamic tissue in the human body: its remarkable cyclical remodelling is essential for the establishment of pregnancy. The most notable events in a woman’s endometrial cycle are menstruation and endometrial repair, regeneration of the endometrium during the proliferative phase, attainment of receptivity by the mid-secretory phase of the cycle and the embryo–maternal interactions that initiate peri-implantation events within the microenvironment of the uterine cavity. I have contributed to understanding the molecular and cellular changes underpinning these events, and how disturbance of them leads to menstrual disorders, infertility and endometrial diseases including abnormal uterine bleeding, endometriosis and endometrial cancer. My team has contributed to changes in clinical IVF practice, to a new diagnostic for endometrial receptivity in infertile women and to enhancing endometrial repair. I have shared my world with many amazing younger scientists: it has indeed been a privileged journey.

Introduction

My first introduction to the topic of reproductive processes was as a young research assistant working with Professor Henry Burger and the late Dr James R Goding Sr at the then Medical Research Centre at Prince Henry’s Hospital in Melbourne, Australia. This was at the start of the 1970s when the technique of radioimmunoassay (RIA), first developed by Sol Berson and Rosalyn Yalow (Berson & Yalow 1968), was being applied to reproductive hormones. With Henry Burger, I developed the first RIA for ovine FSH which enabled recognition of its pulsatile release (Salamonsen et al. 1973). I became fascinated by the physiology of reproduction, and later, after a substantial period out of the workforce for motherhood (as common in those days), I undertook a PhD under the supervision of Professor Jock Findlay at Prince Henry’s Institute of Medical Research. He had an interest in embryo implantation and I took up a project to examine molecular mechanisms underpinning implantation in sheep. This work, which focussed on identifying endometrial protein changes in ovine tissue and uterine fluid under different steroidal stimulation and during very early pregnancy (Salamonsen et al. 1985, 1986), stimulated and underpinned my subsequent long-term interest in endometrial function and strong focus on improving female reproductive health.

Over the next 30 years my interests evolved, in part by identifying clinical needs for basic science that would underpin and modify evidence-based clinical practice to improve women’s reproductive wellbeing and also in response to availability of funding. Another strong driver was the opportunity to perform more complex molecular and cellular analyses as new technologies became available.

My specific interests have focussed around the extensive remodelling that occurs within the endometrium, particularly the mechanisms underpinning menstruation and abnormal uterine bleeding and development of endometrial receptivity for successful embryo implantation, in addition to unravelling the microenvironment of implantation within the uterine cavity. Given that disturbances of endometrial remodelling severely affect women's health, my team has also contributed to our understanding of infertility, endometriosis and endometrial cancer. Further, we have identified a number of targets for new women-centred non-steroidal contraceptives: regretfully, funding bodies and pharmaceutical companies in the western world are not yet accepting of post-coital contraception. Some of our discoveries have laid the groundwork for changes to clinical practice while new models we have developed for the study of ‘human’ problems, which cannot be studied in vivo, have subsequently been adapted by
Box 1: Professor Lois A Salamonsen

Lois has spent her professional life following her passion: understanding the cellular and molecular events that underpin the extraordinary cyclical remodelling of the human endometrium.

She obtained her BSc(hons) in biochemistry at Otago University in New Zealand, where she met her lifelong partner Bob Salamonsen. He and the two sons that followed their marriage have provided continuous support and encouragement to her career. The first 10 years focussed on his career development in medicine, which led them to Melbourne, Bergen and Manchester (UK) – in all of these she worked as a research assistant in various laboratories which provided her with a wealth of laboratory skills. On return to Melbourne where they made their home, and with the boys now at school, she obtained a PhD from Monash University and subsequently developed her own laboratory at Prince Henry’s Institute.

Lois’s career was funded through the Fellowship scheme of NHMRC of Australia where she finally became Senior Principal Research Fellow (NHMRC, 2006-2016). When the Hudson Institute for Medical Research was created through merger of two Institutes, she was appointed Head of the Centre for Reproductive Health. She is also adjunct Professor in the Department of Obstetrics and Gynaecology at Monash University. While now partly retired she still heads the Endometrial Remodelling Laboratory at the Hudson Institute.

Her honours include election as a fellow of The Australian Academy of Sciences (FAA); the Royal Australasian College of Obstetrics and Gynaecology; the Society for the Study of Reproduction (USA) and the Society for Reproductive Biology (SRB, Australasia). She is recipient of the Beacon award from Frontiers in Reproduction and the Founder’s lecture of the SRB.

Her team, through >260 publications, are recognized for their contributions to our understanding of endometrial remodelling, the mechanisms underlying menstruation and abnormal uterine bleeding, uterine receptivity, embryo implantation, along with new approaches to female contraception as detailed in the accompanying article. Their focus is on the human, with strong emphasis on translational research.

Current research focuses on the microenvironment of implantation. Identification of the proteins and exosomes in uterine fluid, their regulation and functions both on the endometrium and on the developing embryo and trophoblast, is providing insights into the complexity of implantation and how it is disturbed in infertile women. The demonstration of strongly detrimental effects of the ovulation induction regimes used in IVF clinics on endometrial receptivity and the potential for implantation, combined with new tests to predict receptivity, should lead to changes in clinical practice and improved IVF outcomes.

Lois has a passion for training young scientists, with a number of her trainees subsequently developing highly productive careers. Some now hold professorial appointments worldwide. Equally, she guides others to appropriate and fulfilling careers outside of research: the adage that a PhD provides important skills beyond just the research, that can be applied broadly, and that a scientifically informed population is important to society as a whole. Lois is particularly known for her mentorship of young women, who face difficult decisions in combining motherhood and childcare with a high-pressure career in scientific research. She comes to this from her own life experience, which even starting a PhD at 40 years is not prohibitive of a productive life in science.

This life has been a privilege and a joy – who could ask for more.

Some important articles


Understanding human endometrial function

Mechanisms of menstruation and endometrial repair

Menstruation is the process whereby most of the functionalis layer of the endometrium is shed, accompanied by bleeding from the fragmented blood vessels, at the end of each non-conception menstrual cycle (reviewed: Salamonsen 2018). It occurs in only a limited number of species including women, old world primates, some bats and the spiny mouse (Bellofiore et al. 2018) and is a response to the rapid fall in levels of progesterone and estradiol-17β that accompany the demise of the corpus luteum. Current knowledge indicates that menstruation is limited to these species, since they are the only ones in which the endometrial stroma undergoes the process of differentiation known as decidualization, during the secretory phase, even in the absence of an embryo. Since this is irreversible, the endometrium must be shed and replaced to provide an opportunity for implantation in the next cycle. Menstrual shedding, as observed by scanning electron microscopy (Ferenczy & Richart 1973, Ludwig & Spornitz 1991), occurs at focal points, with rapid re-epithelialisation of the shed surface occurring even as shedding is initiated at adjacent sites. The first day of bleeding is by definition, day 1 of the next menstrual cycle.

Figure 1 The menstrual cascade is a highly controlled process of inflammation and tissue degradation. In brief, during the late secretory phase of the cycle and in the absence of a pregnancy, the falling levels of progesterone and estrogen stimulate production of chemokines and cytokines by endometrial decidualized stromal cells and epithelial cells. These result in entry of large numbers of leukocytes into the tissue, which become activated locally and stimulate production of degradative enzymes, particularly matrix metalloproteinases in their latent forms which also become activated. These then degrade the extracellular matrix of the tissue, resulting in shedding and concomitant bleeding. The photomicrographs show (A) staining of menstrual tissue with CD45, indicating that 40–50% of the cells in the tissue are of leukocyte origin; (B) inactive mast cells in the tissue, become activated releasing their granular contents (shown here staining for mast cell tryptase); (C) in situ zymography of day 2 menstrual tissue, indicating active MMP2 and MMP9, at very focal points in the tissue, thus explaining the piecemeal tissue shedding.

Menstrual breakdown

The withdrawal of steroidal control of the endometrium initiates a sequence of events leading to menstrual breakdown (Fig. 1), and these events represent a highly controlled inflammatory process (Finn 1986). Progesterone is an inhibitor of inflammation, as evidenced in mice lacking the progesterone receptor (PR) in which the uterus is highly inflamed (Lydon et al. 1995). The initial response to falling progesterone in a non-conception cycle (when the corpus luteum is not rescued by hCG), occurs within the decidualized stromal cells, which express the PR and respond to progesterone withdrawal by intracellular processes known for their role in inflammation. These include decreased cytoplasmic I-kappaB and a progressive increase in NF-kappaB accumulation in the nucleus. In parallel, a host of pro-inflammatory mediators, including chemokines and cytokines, are released: this can be abrogated by an inhibitor of NF-kappaB (Evans et al. 2011, Evans & Salamonsen 2012).
Leukocytes are present in the endometrium in only small numbers during the proliferative phase of the cycle, but uterine natural killer cells (uNKs), increase in the mid-secretory phase with their proliferation and differentiation occurring in response to IL15 induced by progesterone acting on the stromal cells (Kitaya et al., PMID:15713701); these are associated with endometrial receptivity. However, during the late secretory phase, in response to progesterone withdrawal and the chemokines and cytokines released into the tissue from the decidualized cells, there is a massive influx of inflammatory cells including macrophages (Fig. 1A), but predominantly granulocytes (neutrophils, mast cells, eosinophils, basophils), which become activated locally (Fig. 1B). These release not only factors such as degradative enzymes and cytokines stored in their intracellular granules but also chemo-attractants for uNK and monocytes/macrophages (Salamonsen & Woolley 1999). These inflammatory cells comprise up to 50% of the total cells in peri-menstrual endometrium and set up a cascade of events that lead to tissue destruction. Since uNK cells predominate prior to the menstrual cascade, their major role is most likely during pregnancy when they are important components of pregnancy decidua that orchestrate vascular adaption and trophoblast invasion (Hanna et al. 2006, Xiong et al. 2013). However, there is evidence that within the late secretory phase of the cycle, once decidualization has commenced, the uNK cells selectively target and clear senescent decidual cells through granule exocytosis (Brighton et al. 2017).

Extracellular matrix breakdown

Matrix metalloproteinases (MMP) are the family of enzymes primarily responsible for breakdown of extracellular matrix: different enzymes have specific substrate specificities. The first indication of the in vivo association of MMPs with menstruation, using Northern blot on endometrial samples taken from across the cycle, showed clearly that MMP1 and MMP3 mRNA were highly expressed only immediately before and during menstruation (Hampton & Salamonsen 1994) and, subsequently, we and others identified a range of MMP mRNA and protein capable of fully breaking down the endometrial ECM in peri-menstrual endometrium (Rodgers et al. 1994, Jezierska et al. 1996, Marbaix et al. 1996). MMP expression in human endometrium is regulated both by withdrawal of progesterone (Marbaix et al. 1992, Zhang et al. 2000) and also by locally produced cytokines including IL1β and TNFα (Rawdanowicz et al. 1994). MMPs are released as latent forms requiring extracellular cleavage for activity: in vivo they are balanced by natural inhibitors (TIMPs) that bind the active forms with a 1:1 stoichiometry. This provides stability of tissues as it is only when active MMPs are present in excess of the TIMPs that ECM degradation can occur. MMP activators include other MMPs (providing a cascade of activity), enzymes from leukocytes including mast cell chymase and trypase and cytokines (Salamonsen & Lathbury 2000; Fig. 1B, Zhang et al. 1998). Using in situ zymography, focal sites of MMP activity were demonstrated in menstrual endometrium, supporting that MMPs that are likely primarily responsible for tissue degradation at menstruation while the focal activation highlights the mechanism underpinning the piecemeal nature of menstrual tissue breakdown (Fig. 1C; Zhang & Salamonsen 2002). New mechanisms by which MMPs are so tightly regulated are emerging, and include inhibition of endocytic clearance by the low-density lipoprotein receptor-related protein-1 (LRP-1) by ectodomain shedding (Gaide Chevrhonnay et al. 2012).

Mouse models of menstruation

Since it is possible to undertake only ‘snapshots in time’ of endometrial tissue in women, a good animal model for menstruation is needed. Colin Finn (Finn & Pope 1984) first developed a mouse model for menstruation, providing proof that both progesterone withdrawal and artificial decidualization (which occurs only in response to an embryo in mice), were essential for menstrual breakdown. This was refined by us in the early 2000s (Brasted et al. 2003) and has since been modified by others (Menning et al. 2012, Xu et al. 2013, Cousins et al. 2014, Armstrong et al. 2017) providing insights into molecular and cellular mechanisms of breakdown and repair detailed below.

Recently, the spiny mouse, a native to the deserts of Africa and the Middle East, has been shown to undergo menstruation very similar to that in women. It demonstrates similar variation in degree of menstrual bleeding with some females having noticeable heavy periods along with inflammation, breakdown and repair processes as in women. This menstruation occurs for approximately 72 h every 9 days (Bellofiore et al. 2018), making this a very useful laboratory model for study of the human condition.

Endometrial repair

Redevelopment of Finn’s mouse model of menstruation, particularly enabled molecular evaluation of endometrial repair, which is essential to stop menstrual bleeding and which, uniquely, is scar free. As previously shown in menstruating women by scanning electron microscopy, endometrial repair in the mouse model occurs simultaneously at focal points, adjacent to those which are still undergoing breakdown. Importantly, initial repair (re-epithelialisation) can take place in the complete absence of estrogen (Kaitu’u-Lino et al. 2007a) but is hampered by androgen (Cousins et al. 2016). Furthermore, activins stimulate repair (Kaitu’u-Lino et al. 2018).
et al. 2009) and neutrophil influx is essential (Kaitu’u-Lino et al. 2007b). In a similar mouse model, physiological endometrial hypoxia and decreased HIF-1α occur during bleeding while maintenance of the mice under hyperoxia during menses both decreases HIF-1α induction and delays repair (Maybin et al. 2018). In a unique approach, Jemma Evans proposed that as repair occurs in the presence of menstrual effluent, this fluid would contain repair factors. Application of menstrual fluid to in vitro endometrial wound models dramatically enhanced re-epithelialization. Differential proteomic analysis of menstrual serum vs blood serum (collected at the same time) identified both unique and upregulated proteins in menstrual serum. These included proteases, anti-proteases, antimicrobials and factors protective against stress, along with others that could be predicted to facilitate post-menstrual repair. Indeed, a number of the identified proteins were functionally active in promoting endometrial repair in vitro (Evans et al. 2018).

Abnormal uterine bleeding
Abnormal uterine bleeding (AUB) is a major issue for women and their families. In women using long-acting progestin-only contraceptives (such as the implantable Implanon and the impregnated IUD, Mirena), AUB primarily takes the form of irregular spotting. However, such irregularity is the major reason for women discontinuing these very effective contraceptives. With support from the World Health Organisation, we and others investigated the mechanisms underpinning this bleeding. One cause identified was inadequate control of MMP actions by different mechanisms: local disturbance of TIMPs and excessive leukocyte activation (Vincent et al. 1999, 2000). Regrettably, clinical trials of treatments for frequent and/or controlled bleeding in women using Implanon, based on this knowledge (Weisberg et al. 2006, 2009), showed that while mifepristone combined with ethinyl estradiol or doxycycline (which inhibits MMP action) was effective in stopping a specific bleeding episode, it showed no improvement in subsequent bleeding episodes.

In users of hormone replacement therapy, irregular bleeding is also associated with a distinct pattern of MMP and TIMP production, but this differs from that seen in normal menstrual bleeding and from that seen in contraceptive-related breakthrough bleeding. Again, evidence supports that the balance between MMP and TIMP in the endometrium contributes to vascular breakdown with HT but by a different mechanism than that seen in normal menstruation or in breakthrough bleeding (Hickey et al. 2006).

There is still a clear need for treatments for abnormal uterine bleeding. It is to be hoped that others will continue this quest using new knowledge and models.

Endometrial receptivity for implantation
Cyclical remodelling is the major feature of the endometrium in most, if not all, species but is most extreme in women. It is driven primarily by the cyclical production of the ovarian hormones estradiol-17β and progesterone and serves to prepare the endometrium for implantation of a blastocyst in a conception cycle. However, the endometrium is ‘receptive’ only for about 4 days (Navot et al. 1991, Wilcox et al. 1999) in the mid-secretory phase of each menstrual cycle. At this time, all the cell types in the endometrium, particularly the epithelial cells and the stromal fibroblasts have differentiated in response to the rising progesterone following ovulation. A receptive endometrium is essential for implantation when a hatched blastocyst attaches to and penetrates the luminal epithelium to begin its invasion through the decidualizing stroma (Fig. 2). It is now clear that at least some of the unexplained infertility in women is a result of failure to attain receptive endometrium. We have sought to identify the critical signalling molecules that lead to receptivity and implantation.
Our first discovery studies for endometrial factors involved in implantation utilized the then new technique of RNA differential display, comparing expression levels in implantation vs inter-implantation sites in mice on day 4.5 of pregnancy, just when the blastocyst was first in contact with the endometrium. Five of the transcripts identified encoded proteins which were further investigated (Nie et al. 2000b), MNSFβ (Nie et al. 2000a), the high temperature-resistant protein A3 (HtrA3; its first identification) (Nie et al. 2003a), pro-protein convertase 5/6 (Nie et al. 2003b), splicing factor SC35 (Nie et al. 2002) and Calbindin d9k (Nie et al. 2000b). Knockdown or inhibition of four of these demonstrated that they were each essential for implantation in mice: all but calbindin d9k were similarly expressed in receptive human endometrium: due to evolution, in women calbindin 28k most likely performs the same role (Luu et al. 2004). PC6 and HtrA3 are both proteases and identification of their specific substrates has provided insight into pathways essential for implantation, potential targets for contraception and a potential use in identifying receptive endometrium (see below).

A key role for cytokines in implantation was first demonstrated in leukaemia inhibitory factor (LIF)-null mice which exhibited failure of implantation (Stewart et al. 1992). Interestingly, extension of this work to human implantation showed that while LIF contributes to receptivity in women, it is not essential (Paiva et al. 2009). Indeed treatment of infertile women with LIF failed to improve implantation rates (Brinsden et al. 2009). We further established that another related cytokine, interleukin (IL)11, whose receptor (R), as for LIFR, is present on endometrial epithelium, and also plays a role in implantation, regulating the adhesiveness of primary endometrial epithelial cells, likely though upregulation of both flotillin-1 and annexin A2 (Yap et al. 2011), which are themselves proposed to be essential for implantation. Furthermore, IL11, IL6 fibroblast growth factor (FGF)2, CXCL10, vascular endothelial growth factor (VEGF) and granulocyte-macrophage growth factor (GMCSF) are all regulated in endometrial epithelium by blastocyst-derived human chorionic growth factor (hCG) (Licht et al. 2001, Paiva et al. 2011), demonstrating the importance of the blastocyst signalling in establishment of pregnancy. IL11 is also one of a number of cytokines, including activin A, that drive decidualization via different pathways (Menkhorst et al. 2010).

The luminal epithelium is the first point of contact of the blastocyst with the endometrium. At the time of implantation, this undergoes a ‘plasma membrane transformation’ (Murphy 2004) accompanied by loss of junctional integrity and adhesive molecule changes at the apical surface (Aplin & Ruane 2017). In women, PC6 acting via its proteolytic activity, post-translationally regulates anti-adhesion molecules (including dystroglycan and integrins (Paule et al. 2012, Heng et al. 2015) and reorganizes the plasma membrane altering the apical architecture to provide a receptive surface (Heng et al. 2011). Further, actin linkage to the apical plasma membrane is regulated by the ERM proteins, ezrin, moesin and radixin (Martin et al. 2000): PC6 cleaves the ERM-binding phosphoprotein EB50, which tethers ezrin to the membrane: knockdown of PC6 stabilizes membrane localization of ERMs, thus preventing the rearrangement of the actin microfilament web essential for receptivity (Heng et al. 2011).

Changes in epithelial apical-basal polarity, first proposed by Denker (Denker 1993), are needed for progression of implantation following adhesion, enabling the trophectodermal cells to move between the epithelial cells and penetrate the stromal compartment. In the endometrial epithelial cell line ECC1 (the closest representative of luminal epithelium), combined estrogen/progesterone treatment to mimic the mid-secretory phase of the cycle downregulated polarity (measured by reduced transepithelial resistance). Importantly, defined polarity markers (Stardust, Crumbs and Scribble) were downregulated in endometrial biopsies during the progression from the proliferative to the secretory phase while knockdown of Scribble in the ECC1 cells, enhanced trophectodermal adhesion (Whitby et al. 2018). Interestingly, this loss of polarity is further driven by hCG, a product of the pre-implantation blastocyst, via its receptor (the LHCGR) on the epithelial cells (Evans & Salamonsen 2013).

Uterine microenvironment of implantation

Uterine fluid provides the microenvironment for blastocyst hatching and final development, and for the first stages of implantation (Salamonsen et al. 2016; Fig. 2). It contains highly selected serum proteins (albumin and immunoglobulins are particularly abundant) (Hannan et al. 2009), along with contributions from fallopian tube fluid, leukocyte activation, semen and the blastocyst (in a conception cycle). Salts, sugars, amino acids, lipids, hormones, carbohydrates, RNA forms and other nutrients are also present. Importantly uterine fluid is enriched in soluble proteins secreted from the endometrial luminal epithelium and glands and in secreted extracellular vesicles (EVs). Analysis of uterine fluid may provide a useful window to detect whether or not receptivity has been achieved (Salamonsen et al. 2013) and to detect diseases of the reproductive tract (Lopata et al. 2003).

Uterine gland secretions are unequivocally required for establishment of pregnancy as shown by landmark studies in sheep (Gray et al. 2001) and mice (Filant & Spencer 2013), in which the development of uterine glands was totally inhibited (uterine gland knockout).
The ewes showed retarded conceptus development and no implantation, while in the female mice, there was no decidualization and no implantation.

In women, the endometrium is rich in glands, with approximately 15 gland openings for every millimetre of uterine surface in the secretory phase (Burton et al. 2002); thus, secretions into the uterine cavity are abundant, particularly during the mid-secretory phase when the glands are fully differentiated for secretion. Analysis of human uterine fluid has utilized either uterine aspirate or lavage: these provide somewhat different results, probably since lavage washes the uterine surface, removing loosely bound molecules or those trapped locally by the glycocalyx (Hannan et al. 2012). Multiplex cytokine/chemokine analyses have measured many of these important mediators in uterine fluid and shown that their levels differ between fertile and infertile women and in the proliferative compared with the secretory phase (Boomsma et al. 2009, Hannan et al. 2011, Fitzgerald et al. 2016). In some cases, functional studies indicated their roles: for example, VEGF promotes human endometrial epithelial cell adhesive capacity and mouse blastocyst outgrowth in vitro and along with placental growth factor (PLGF) enhances embryo development and implantation in mice (Hannan et al. 2011, Binder et al. 2014, 2016).

With the recent advent of sophisticated proteomics, uterine fluid has been examined in an unbiased manner: many proteins already known as important for receptivity have been confirmed, and other novel proteins also identified in secretory phase fluid (Casado-Vela et al. 2009, Scotchie et al. 2009, Hannan et al. 2010). Validation is typically absent while bioinformatics and functional assays could indicate possible actions. Interestingly, proteomic analyses of proliferative phase proteins and glycoproteins have indicated that in some idiopathic infertile women, the endometrium is developing in an environment of increased inflammation, thus inadequately priming the endometrium for development of receptivity (Fitzgerald et al. 2016, 2018) and personal communication). Some of the proteins altered in the proliferative phase were further validated: for example, extracellular matrix protein 1 (ECM1) is secreted by both primary endometrial epithelial and stromal cells and is not regulated by estrogen. It is a biorransporter, binding many partners among which are a number of extracellular matrix proteins; hence, ECM1 may influence endometrial regeneration and development.

To determine the hormonal regulation of uterine fluid proteins, we analysed the soluble secreted proteomes of ECC1 cells, appropriately treated to represent the proliferative (estrogen alone) and secretory phases of the cycle (estrogen plus progesterone following estrogen priming) and also in the presence of the embryo-derived hCG. There were substantial unique protein changes between these. Of 1059 proteins identified, 123 were significantly altered by progesterone (mostly downregulated) (Fig. 3) and 43 proteins were altered by hCG. The identified proteins were associated with cellular adhesion, ECM organisation, developmental growth, growth factor regulation and cell signalling. Many of the changes were validated in primary endometrial epithelial cells (Greening et al. 2016b). Several proteins were common to those in the secretory phase described by Scotchie et al. (2009) and 15 had been identified in our previous analyses (Hannan et al. 2010). Interestingly, the enzymatic protein superoxide dismutase (SOD1), which is an important antioxidant defense, was elevated in response to hCG, and hence, has a potentially important role in endometrial–embryo communication.

**Extracellular vesicles: part of the cellular secretome**

The term ‘secretome of a cell’ has recently been redefined to include the totality of organic and inorganic elements secreted from cells either as soluble forms or within EVs produced via endosomal exocytosis (Wikipedia). EVs are nano-sized particles, released from all cells. They provide communication with other cells, even at some distance, by delivery of their complex cargo via cell-specific docking sites. This alters the phenotype of the recipient cells, contributing to both physiological and pathological processes. Importantly, the molecular ‘cargo’ (that includes RNA, miRNA, DNA, lipids and proteins) is protected from extracellular degradation. EVs can be divided by size and specific marker proteins into apoptotic bodies, microvesicles and exosomes and separated by differential ultracentrifugation. Apoptotic

![Figure 3](https://rep.bioscientifica.com)
bodies are removed at 10,000*g and the others pellet at 100,000*g; it is the latter fraction that is generally used in functional studies. Further separation can be achieved by density gradient centrifugation (Nguyen et al. 2016) to provide the highly purified fractions essential for proteomic analyses.

We were the first to identify EVs in human uterine fluid and that these contained a unique cohort of proteins and miRNA (Ng et al. 2013, Greening et al. 2016a) respectively, differing from those of the parent endometrial epithelial cells. The contents of endometrial epithelial exosomes, prepared from the secretions of ECC1 cells, are programmed by ovarian steroid hormones (as are the soluble secreted products), with the protein profiles differing from those of the soluble secretome and the cellular proteome of the same cells. Analyses of the exosomal proteomes defined a total of 1043 exosomal proteins, of which 254 were regulated by estrogen (E) alone and 126 by combined estrogen plus progesterone (EP). More exosomal proteins were downregulated, than upregulated by EP vs E, and these were in the categories of basement membrane, cell adhesion and extracellular matrix/cytoskeletal proteins (Greening et al. 2016a). Importantly, these endometrial epithelial exosomes have a unique proteome compared with exosomal proteins from other tissues and cancers (www.exocarta.com) with ~10% of the proteins not detected in exosomes from other sources. Functionally, endometrial exosomes are taken up by trophoblast (HTR8) cells, by the trophectodermal stem cell line TSC (Evans J, Greening DW, Salamonsen LA, unpublished observations), by mouse blastocysts (Catt S, Nguyen H, Salamonsen LA, unpublished observations) and also by endometrial epithelial cells themselves (Salamonsen LA, Greening DW, Evans J, Gurung S, Roslee AM unpublished). In the HTR8 cells, exosomal uptake enhanced trophoblast adhesive capacity (as measured by xCelligence) via the Fak-kinase pathway (Greening et al. 2016a), while in mouse blastocysts, exosomal uptake enhanced outgrowth. Most physiologically relevant is that in a human implantation model that quantitates trophectodermal spheroid attachment to an endometrial epithelial cell monolayer (Evans J, Greening DW, Walker KJ, Bilandzic M, Kinnear S, Hutchinson J, Salamonsen LA, submitted), inclusion of endometrial exosomes enhanced both spheroid adhesion and attachment (Evans J, Salamonsen LA, unpublished observations).

Clinical applications

Our emphasis has been on studying human endometrium with a view to clinically relevant outcomes; while many studies have ‘placed another piece in the jigsaw’ of knowledge that will subsequently lead to translation, some have/will have direct clinical implications.

Change in IVF practice to ‘Freeze-all’

Regrettably, infertility clinics have had an embryocentric view since IVF was introduced, with the main aim being to produce a good blastocyst for transfer. However, the endometrium, which is equally as important, has remained the ‘black box of early pregnancy loss’ and indeed implantation (Macklon et al. 2002). In 2014, we presented a strong case for frozen embryo transfer, based on both scientific and clinical evidence (Evans et al. 2014) which underpinned what has been a slow change from previous international practice. In Australia, such ‘freeze-all’ cycles, increased from 5% of fresh cycles in 2011 to almost one in five cycles in 2015, with numbers still rising but statistics not yet available (National Perinatal Epidemiology and Statistics Unit, University of NSW’s Centre for Big Data Research in Health and School of Women’s and Children’s Health maintained on behalf of the Fertility Society of Australia).

The scientific evidence supporting this change came largely from a detailed immunohistochemical study of endometrial biopsies taken at ovum pickup, with final analyses comparing women who did/did not become pregnant following embryo transfer in that IVF cycle. Critically, most tissues were highly disturbed by the hormonal treatments compared with samples from unstimulated women. Only endometrium with a score close to normal controls supported pregnancy (Evans et al. 2012). Furthermore, a separate investigation showed that hCG stimulation of ovulation makes the endometrium refractory to subsequent embryonic hCG signalling, which promotes receptivity (Evans & Salamonsen 2013).

Lifestyle factors influencing women’s fertility

Many lifestyle factors contribute to infertility in both men and women; these include age, nutrition, weight, exercise and environmental exposures. Reduction in cigarette smoking, illicit drug use, alcohol and caffeine consumption are all of proven benefit and some of the underpinning molecular mechanisms are known (Sharma et al. 2013). Obesity is a known risk factor for ovulation defects, but growing evidence implicates obesity in mediating endometrial dysfunction (reviewed in (Antoniotti et al. 2018). By explanation, a family of post-translational modifications of fat- and sugar-related molecules, known as advanced glycation end products (AGEs), which are elevated systemically in women with high BMI, are at high concentrations in the uterine cavity of these women. Importantly, AGEs adversely impact both endometrial function and embryo implantation competence (Antoniotti et al. 2018). Since AGE levels can be lowered by diet (de Courten et al. 2016) or by pharmaceutical means (Coughlan et al. 2007), this
offers hope to those infertile women with obesity and/or related metabolic disorders.

**Blood test for endometrial receptivity**

A major need in IVF clinics is for a test to indicate whether fresh embryo transfer is likely to be successful. Following our extensive analysis of uterine fluid, a cohort of cytokines measured in uterine fluid taken on the day of ovum pickup, has proven to be a highly effective test for uterine receptivity in the cycle of sampling: it clearly differentiates between women who will have a successful transfer in that cycle and those who will not (Edgell et al. 2018). A modification of this test is equally effective if applied to serum samples similarly taken at the time of ovum pickup (Edgell & Salamonsen, unpublished data).

We anticipate that manipulation of the uterine microenvironment using one or more of the factors dysregulated in infertile women may be effective in treating endometrial infertility without need for IVF.

**Beyond the endometrium: scar-free wound repair**

Endometrial repair following menstruation is unique among adult tissues in that it occurs very rapidly and without scarring. Endometrial destruction occurs at focal points and re-epithelialization follows immediately to cover the endometrial surface; thus, repair occurs in the presence of menstrual effluent. From the proteomic data discussed earlier, several menstrual fluid proteins were functionally active in endometrial repair assays (Evans et al. 2018). Testing was also successfully applied to wound repair models, including in vivo wound repair in pigs. Unlike other known wound repair proteins, which promote cellular proliferation and have a potential hazard of stimulating cancers, the menstrual fluid proteins enhanced cellular migration and initial re-epithelialization of wounds. It is predicted that these factors will extend current wound repair paradigms, maybe reducing the risk of scarring and providing effective treatment of chronic non-healing wounds.

**Contraceptive targets**

One major ambition has remained unfulfilled: to provide a novel non-hormonal contraceptive for women that need only be utilized in any cycle in which coitus occurs. In the early 1990s we proposed that maintenance of the endometrium in a non-receptive state throughout the cycle (by inhibiting the development of receptivity), would provide very effective contraception. Funding for such development was available in the 1990s–2000s: we proved that blocking the actions of PC6 and its substrates or IL11 would be effective. PC6 is a particularly exciting target since it is also essential for HIV infectivity through the vagina. Subsequently, numerous other potential targets have been identified. In women, it is difficult to directly target the endometrium or uterine cavity. The teams of Nie and Dimitriadis, working with inhibitors of PC6 and IL11, respectively, investigated modes for local administration in mice, particularly vaginal gels which could provide simultaneous protection from pregnancy and infection (Menkhorst et al. 2011, Ho et al. 2014). The inhibitors used were effective and clearly reached the mouse endometrium via a ‘first pass effect’ from the vaginal circulation. Whether this would also be the case in women is not known: progestins which are of very low molecular weight can be delivered via the vagina. We now anticipate that delivery of inhibitors via exosomes/nanoparticles with target specificity to endometrial epithelium (a current major interest of ours) may provide a solution to local delivery. A major advantage of targeting the endometrium is that it is shed in each menstrual cycle and thus actions of inhibitors in one cycle would not be maintained and hence not be systemically harmful.

The major obstacles remaining to achieve such contraception are twofold. Firstly systems for direct delivery to the uterine cavity need to be developed, and secondly, the political demands that contraception for women be targeted only at pre-fertilization events need to be overcome. This is clearly regrettable in a world where non-steroidal contraceptive methods for women remain a global need and in which a majority of women are not confined by the values of a few (Crosignani & Glasier 2012). Indeed, promotion of family planning so that women can avoid unwanted pregnancy is central to achieving the Millennium Development Goal on improving maternal health, reducing child mortality and eliminating extreme poverty (Cleland et al. 2006).

**Conclusions**

It has been a privilege and a great pleasure to contribute to our knowledge of endometrial function and women’s health. However, this would not have been possible without the many others working in the field, a number of whom have become collaborators and friends. Together we have built a strong body of knowledge from which clinical solutions to a number of disorders affecting women will evolve and which will resolve often ‘silent suffering’. My generation’s field of endeavour is now passing to the hands of the wonderful younger scientists we have trained: I have every confidence that they will deliver the important outcomes needed.

**Declaration of interest**

The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Funding
Current funding for the Salamonsen laboratory is from the NHMRC of Australia (Project grant #1139489, Development grant # 1159714), and the Victorian Government Operational Infrastructure Research Support to the Hudson Institute of Medical Research.

Acknowledgements
I particularly acknowledge and thank all the students, postdoctoral scientists and senior scientists who have contributed to the work from my laboratory, as discussed here. Many have now progressed to independent and highly successful careers. It has been my great pleasure to work with each of them.

References


Cousins FL, Murray A, Esnal A, Gibson DA, Critchley HO & Saunders PT 2014 Evidence from a mouse model that epithelial cell migration and mesenchymal-epithelial transition contribute to rapid restoration of uterine tissue integrity during menstruation. PloS ONE 9 e86378. (https://doi.org/10.1371/journal.pone.0086378)


Received 1 October 2018
First decision 5 November 2018
Revised manuscript received 27 November 2018
Accepted 6 December 2018